Y-MABS Therapeutics, Inc. 984241109 07/11/2025 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 2292049 0 FOR 2292049 FOR Verona Pharma PLC 925050106 09/24/2025 To approve, on an advisory, non-binding basis, the compensation that may be paidor become payable to the Company's named executive officers in connection withthe Transaction, as disclosed in the table entitled "Potential Payments to NamedExecutive Officers" beginning on page 70 of the proxy statement, including theassociated narrative discussion, and the agreements or understandings pursuantto which such compensation may be paid or become payable. SECTION 14A SAY-ON-PAY VOTES ISSUER 1000 0 FOR 1000 FOR Murus N.V. N5749R100 12/09/2025 Non-binding advisory proposal to approve certain compensation arrangements SECTION 14A SAY-ON-PAY VOTES ISSUER 216954 0 FOR 216954 FOR Abivax SA 00370M103 05/11/2026 Approval of the compensation items mentioned in Article L. 22-10-9 I of the French Commercial Code, pursuant to Article L. 22-10-34 of the French Commercial Code (8th resolution) SECTION 14A SAY-ON-PAY VOTES ISSUER 1307961 0 FOR 1307961 FOR Abivax SA 00370M103 05/11/2026 Approval of the compensation items paid during, or allocated for, the financial year 2025 to Ms. Sylvie Grégoire as Chair of the Board of Directors (9th resolution), SECTION 14A SAY-ON-PAY VOTES ISSUER 1307961 0 FOR 1307961 FOR Abivax SA 00370M103 05/11/2026 Approval of the compensation items paid during, or allocated for, the financial year 2025 to Mr. Marc de Garidel as Chief Executive Officer (10th resolution), SECTION 14A SAY-ON-PAY VOTES ISSUER 1307961 0 FOR 1307961 FOR Abivax SA 00370M103 05/11/2026 Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code (11th resolution), SECTION 14A SAY-ON-PAY VOTES ISSUER 1307961 0 FOR 1307961 FOR Abivax SA 00370M103 05/11/2026 Approval of the compensation policy applicable to the Chair of the Board of Directors (12th resolution), SECTION 14A SAY-ON-PAY VOTES ISSUER 1307961 0 FOR 1307961 FOR Abivax SA 00370M103 05/11/2026 Approval of the compensation policy applicable to the Chief Executive Officer (13th resolution), SECTION 14A SAY-ON-PAY VOTES ISSUER 1307961 0 FOR 1307961 FOR Abivax SA 00370M103 05/11/2026 Approval of the compensation policy applicable to the Board members (14th resolution), SECTION 14A SAY-ON-PAY VOTES ISSUER 1307961 0 FOR 1307961 FOR ADC Therapeutics SA H0036K147 06/01/2026 Approving, on an advisory basis under U.S. law, the compensation paid to our Named Executive Officers. The Board of Directors proposes that the following proposal: "RESOLVED, that the Company's Shareholders approve, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in "Executive Compensation" and the related compensation tables and narrative disclosure in this proxy statement", be approved. SECTION 14A SAY-ON-PAY VOTES ISSUER 1805000 0 FOR 1805000 FOR ADMA Biologics, Inc. 000899104 06/02/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 4109865 0 FOR 4109865 FOR Anika Therapeutics Inc. 035255108 06/18/2026 Advisory vote on the compensation of the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 1293059 0 FOR 1293059 FOR Exelixis, Inc. 30161Q104 05/26/2026 To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy Statement SECTION 14A SAY-ON-PAY VOTES ISSUER 752768 0 FOR 752768 FOR LIQUIDIA CORPORATION 53635D202 06/16/2026 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1842357 0 FOR 1842357 FOR Vaxcyte, Inc. 92243G108 06/15/1026 Approval, on a non-binding, advisory basis, of the compansation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 572780 0 FOR 572780 FOR REVOLUTION MEDICINES, INC. 76155X100 06/18/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 1583652 0 FOR 1583652 FOR Spyre Therapeutics Inc. 00773J202 05/27/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 662832 0 FOR 662832 FOR Tango Therapeutics, Inc. 87583X109 06/04/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1777433 0 FOR 1777433 FOR VERRICA PHARMACEUTICALS INC. 92511W108 06/05/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 816572 0 FOR 816572 FOR XENON PHARMACEUTICALS INC 98420N105 06/02/2026 To approve, on an advisory basis, the compensation of the Corporation's namedexecutive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1122615 0 FOR 1122615 FOR XENON PHARMACEUTICALS INC 98420N105 06/02/2026 To approve, on an advisory basis, the frequency of future shareholder advisoryvotes to approve the compensation of the Corporation's named executive offi cers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1122615 0 FOR 1122615 FOR Inventiva S.A. 46124U107 06/30/2026 Final approval for the fixed and varriable compensation paid or awarded to Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors for the financial year ended December 31, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 4527504 0 FOR 4527504 FOR Inventiva S.A. 46124U107 06/30/2026 Final approval for the fixed and varriable compensation paid or awarded to Mr. Frèdèric Crenin his capacity as Chief Executive Officer, until September 30, 2025, for the financial year ended December 31, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 4527504 0 FOR 4527504 FOR Inventiva S.A. 46124U107 06/30/2026 Final approval for the fixed and varriable compensation paid or awarded to Mr. Andrew Obenshain his capacity as Chief Executive Officer, from October 1, 2025, for the financial year ended December 31, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 4527504 0 FOR 4527504 FOR Inventiva S.A. 46124U107 06/30/2026 Final approval for the fixed and varriable compensation paid or awarded to Mr. Pierre Broqua his capacity as Deputy Chief Executive Officer, until June 30, 2025, for the financial year ended December 31, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 4527504 0 FOR 4527504 FOR Inventiva S.A. 46124U107 06/30/2026 Approval of the information on corporate officers' compensation included in the corporate goverance report and referred to in Article L.22-10-9 I. of the French Commercial Code SECTION 14A SAY-ON-PAY VOTES ISSUER 4527504 0 FOR 4527504 FOR Inventiva S.A. 46124U107 06/30/2026 Approval of the compensation policy for Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors. SECTION 14A SAY-ON-PAY VOTES ISSUER 4527504 0 FOR 4527504 FOR Inventiva S.A. 46124U107 06/30/2026 Approval of the compensation policy for Mr. Andrew Obenshain in his capacity as Chief Executive Officer. SECTION 14A SAY-ON-PAY VOTES ISSUER 4527504 0 FOR 4527504 FOR Inventiva S.A. 46124U107 06/30/2026 Total compensation paid to members of the Board of Directors. SECTION 14A SAY-ON-PAY VOTES ISSUER 4527504 0 FOR 4527504 FOR Inventiva S.A. 46124U107 06/30/2026 Approval of the compensation paid to members of the Board of Directors. SECTION 14A SAY-ON-PAY VOTES ISSUER 4527504 0 FOR 4527504 FOR